PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Sandoz, Inc, Princeton, NJ.\', \'Xcenda, LLC, Palm Harbor, FL.\', \'Fred Hutchinson Cancer Research Center, Seattle, WA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1200/OP.20.01047
?:doi
?:hasPublicationType
?:journal
  • JCO oncology practice
is ?:pmid of
?:pmid
?:pmid
  • 33793342
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all